Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monogram Orthopaedics Inc (MGRM)
NASDAQ:MGRM
RESEARCH TOOLSreports
Holding MGRM?
Track your performance easily
Earnings Data
Report Date
Mar 14, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.12Last Year’s EPS
$0.09Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 28.36%
|Next Earnings Date:Mar 14, 2025
Earnings Call Sentiment|Positive
Monogram Technologies reported strong financial health with a successful fundraising effort and continued progress on regulatory and clinical trial fronts. However, challenges with FDA's additional information request and temporarily elevated marketing expenses were noted.Company Guidance
During the third quarter earnings call for Monogram Technologies, CFO Noel Knape provided detailed financial guidance, highlighting key metrics. The company ended Q3 2024 with $16.5 million in cash and a year-to-date operating cash flow of $10.9 million, which translates to a monthly cash run rate of $1.2 million. Remarkably, Monogram raised $13.99 million from financing activities, primarily through a successful preferred D raise, initially targeting $10 million but oversubscribing to $13 million. The company maintains a workforce of 27 full-time employees, with additional engineering staff being outsourced as needed, and holds no traditional debt. The anticipated cost for an out-of-U.S. clinical trial is approximately $1.2 million, integrated into the monthly run rate. This financial positioning, alongside the recent capital raise, provides Monogram with sufficient resources to meet short-term milestones and conclude the year with a robust balance sheet.Successful Financial Raise
Monogram Technologies raised $13.99 million from financing activities, exceeding their target of $10 million.
FDA Submission Progress
The company submitted their first 510(k) application to the FDA ahead of schedule and received an Additional Information Request (AIR) from the FDA, which was expected.
Out-of-US Clinical Trial Plans
Plans to conduct a clinical trial in India with Shalby to perform surgeries on 102 subjects, with the trial cost estimated at $1.3 million.
No Traditional Debt
Monogram Technologies continues to have no traditional debt and minimal short-term warrant obligations.
---
MGRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MGRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $2.01 | $2.05 | +1.99% |
| Aug 14, 2024 | $2.70 | $2.79 | +3.33% |
| May 14, 2024 | $1.90 | $2.03 | +6.84% |
| Mar 15, 2024 | $2.01 | $2.10 | +4.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Monogram Orthopaedics Inc (MGRM) report earnings?
Monogram Orthopaedics Inc (MGRM) is schdueled to report earning on Mar 14, 2025, TBA Not Confirmed.
What is Monogram Orthopaedics Inc (MGRM) earnings time?
Monogram Orthopaedics Inc (MGRM) earnings time is at Mar 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MGRM EPS forecast?
MGRM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.12.
---